Lundbeck to Research Link Between Immune System and Brain Diseases
H. Lundbeck A/S (Lundbeck) is involved in new research that will investigate a novel link that could show a relationship between the immune system and mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer's disease. This project, a public-private partnership also involving The Wellcome Trust, Cambridge University and pharmaceutical company Janssen, may be the first step towards a new and significantly improved treatment for a broad range of brain diseases.
The main theory that the project will investigate is that the immune system can worsen brain diseases like depression and Alzheimer's disease. An imbalance in the immune system of the brain can drive a permanent and unhealthy neuro-inflammation — or inflammation in the brain — that can contribute to or cause brain diseases. Another sub-theory for investigation is that the immune system can improve brain diseases if it is triggered in the right way.
The initial link between the immune system and brain diseases has been established by a number of studies, which show that for some sub-groups of patients anti-inflammatory drugs have a positive effect. Some research indicates the presence of increased inflammatory cells and substances in brains of patients, and that anti-inflammatory drugs could decrease depressive symptoms without increasing the risks of adverse effects. This is interesting because a large number of patients today are still not receiving adequate treatment with the existing drugs. However, why and how some patients seem to benefit from receiving certain anti-inflammatory drugs is unclear and that is part of what this project will investigate.
"Neuro-inflammation has been increasingly implicated as a key player in a wide range of brain disorders including depression and Alzheimer's disease. This partnership is an exciting opportunity for us to increase our understanding of the important role of emerging immune and neuronal interactions in these disorders. We believe it can point us toward new avenues to develop breakthrough treatments for the patients," says Dr Stevin Zorn, EVP Lundbeck Research USA.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance